Lung disorder
Therapeutic area
Pulmonology
Rare disease
No
- Definition
- A disease involving the lung.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Lung disorder
- Therapeutic area
- Pulmonology
- lung disorder
- disease of lung
- disease or disorder of lung
- disorder of lung
- lung disease
- lung disease or disorder
- lung disorder
- lung disorders
- pulmonary disease
- pulmonary diseases
- pulmonary disorder
- pulmonary disorders
- All therapeutic areas
- Pulmonology
- Severity
- Mild
- MONDO ID
- MONDO:0005275
- Parent condition
- MONDO:0000270
Related records
Broader conditions (5)
- Disease
- Disease by body system or component
- Human disease
- Lower respiratory tract disorder
- Respiratory system disorder
Narrower conditions (301)
- Acinar lung adenocarcinoma
- Acute bronchiolitis
- Acute chest syndrome
- Acute fibrinous and organizing pneumonia
- Acute interstitial pneumonia
- Acute lung injury
- Acute respiratory distress syndrome
- Acute respiratory failure
- Adenosquamous lung carcinoma
- Adiaspiromycosis
- Adult acute respiratory distress syndrome
- Adult pulmonary Langerhans cell histiocytosis
- Alveolar capillary dysplasia with misalignment of pulmonary veins
- Alveoli adenoma
- Anaerobic pneumonia
- Anthracosilicosis
- Anthracosis
- Asbestos-related lung carcinoma
- Asbestosis
- Aspiration pneumonia
Trials (1,253)
- "Breathlessness Diagnostics in a Box" (BiaB) for Primary Care. A Multi-country Quality Improvement Project Using a Randomized Stepped-wedge Design
- (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
- (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
- (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
- 129 Xenon MRI in Chronic Lung Disease
- 23andMe IPF Research Study
- 3D-printed Reconstruction Automated Matching System Predicts Size of Double-lumen Tube: a Prospective Double-blinded Randomized Controlled Trial
- 4-PBA: Will it Increase the Level of Alpha 1-Antitrypsin(AAT) in Persons With AAT Deficiency?
- A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.
- A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis
- A Brief SMART Exercise Instant Messaging Support Intervention - a Pilot Study
- A Case Controlled Etiologic Study of Sarcoidosis (ACCESS)
- A Clinical Study Aiming to Validate the Equipment: VoluSense Pediatrics (VSP)
- A Clinical Study of LUNG-CT CAD Decision Support
- A Comparative Study Between Regional Anesthesia in Thoracoscopes and the Conventional General Anesthesia
- A Comprehensive Approach To Relief Of Digestive Symptoms In Cystic Fibrosis: CARDS-CF
- A Continuation Study of the AeriSeal® System Administered at 3 to 4 Sites During a Single Treatment Session for Lung Volume Reduction in Patients With Advanced Emphysema
- A Culturally-Based Palliative Care Tele-consult Program for Rural Southern Elders
- A Dietitian-Driven Unified Nutritional Care Model (ADDUCE)
- A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension
Approved drugs (9)
- .ALPHA.1-proteinase inhibitor human
- Albumin human
- Amikacin sulfate
- Beractant
- Calfactant
- Doxapram hydrochloride
- Itraconazole
- Pirfenidone
- Poractant alfa
Drugs in development (55)
- 552-02 Phase 1
- Albuterol Phase 3
- Albuterol sulfate Phase 1
- Amelubant Phase 2
- Amikacin Phase 2
- Amphotericin B Phase 3
- Azathioprine Phase 2
- AZD2423 Phase 2
- Azithromycin Phase 3
- Bedaquiline Phase 2
- Bupivacaine Early phase 1
- Catequentinib Phase 2
- Cefoxitin Phase 2
- Ceftolozane Phase 3
- Ciprofloxacin Phase 1
- Clarithromycin Phase 2
- Clofazimine Phase 2
- CO-trimoxazole Phase 2
- Colchicine Phase 3
- Cyclophosphamide Phase 3
Other linked drugs (4)
- Alfentanil
- Brensocatib
- Propofol
- Propyliodone